{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:04:07Z","timestamp":1740107047854,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00520-022-06967-x","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T11:04:20Z","timestamp":1651143860000},"page":"6327-6338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8924-7218","authenticated-orcid":false,"given":"Jennifer","family":"Schenfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TingTing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kelsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad","family":"Gawade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"issue":"9","key":"6967_CR1","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1007\/s00520-020-05295-2","volume":"28","author":"PL Gawade","year":"2020","unstructured":"Gawade PL, Li S, Henry D et al (2020) Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 28(9):4413\u20134424","journal-title":"Support Care Cancer"},{"issue":"15","key":"6967_CR2","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","volume":"42","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433\u20132453","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"6967_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-200262001-00001","volume":"62","author":"DC Dale","year":"2002","unstructured":"Dale DC (2002) Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 62(Suppl 1):1\u201315","journal-title":"Drugs"},{"issue":"3","key":"6967_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol\/Hematol 90(3):190\u2013199","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"9","key":"6967_CR5","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/cncr.25691","volume":"117","author":"GH Lyman","year":"2011","unstructured":"Lyman GH, Kuderer NM, Crawford J et al (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117(9):1917\u20131927","journal-title":"Cancer"},{"key":"6967_CR6","doi-asserted-by":"crossref","unstructured":"Lyman GH, Kuderer NM, Crawford J et al (2006) Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy. J Clin Oncol 24(18_suppl):8561\u20138561","DOI":"10.1200\/jco.2006.24.18_suppl.8561"},{"key":"6967_CR7","doi-asserted-by":"crossref","unstructured":"Mhaskar R, Clark OA, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B (2014) Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 10:CD003039","DOI":"10.1002\/14651858.CD003039.pub2"},{"issue":"21","key":"6967_CR8","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158\u20133167","journal-title":"J Clin Oncol"},{"issue":"6","key":"6967_CR9","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178\u20131184","journal-title":"J Clin Oncol"},{"issue":"3","key":"6967_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325(3):164\u2013170","journal-title":"N Engl J Med"},{"key":"6967_CR11","doi-asserted-by":"crossref","unstructured":"Crawford J, Becker PS, Armitage JO et al (2017) Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(12):1520\u20131541","DOI":"10.6004\/jnccn.2017.0175"},{"issue":"1","key":"6967_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332","journal-title":"Eur J Cancer"},{"issue":"4","key":"6967_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427\u2013431","journal-title":"Clin Infect Dis"},{"issue":"28","key":"6967_CR14","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"issue":"7","key":"6967_CR15","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1200\/JCO.2007.14.2885","volume":"26","author":"RE Smith Jr","year":"2008","unstructured":"Smith RE Jr, Aapro MS, Ludwig H et al (2008) Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26(7):1040\u20131050","journal-title":"J Clin Oncol"},{"issue":"11","key":"6967_CR16","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1007\/s00520-019-04725-0","volume":"27","author":"K Laribi","year":"2019","unstructured":"Laribi K, Badinand D, Janoray P et al (2019) Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study. Supportive Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 27(11):4283\u20134292","journal-title":"Supportive Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"1","key":"6967_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3816\/CLM.2001.n.011","volume":"2","author":"VA Morrison","year":"2001","unstructured":"Morrison VA, Picozzi V, Scott S et al (2001) The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin\u2019s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2(1):47\u201356","journal-title":"Clin Lymphoma"},{"issue":"5","key":"6967_CR18","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1200\/JCO.2001.19.5.1583","volume":"19","author":"L Balducci","year":"2001","unstructured":"Balducci L, Lyman GH (2001) Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol 19(5):1583\u20131585","journal-title":"J Clin Oncol"},{"issue":"16","key":"6967_CR19","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/S0959-8049(03)00662-2","volume":"39","author":"L Repetto","year":"2003","unstructured":"Repetto L, Biganzoli L, Koehne CH et al (2003) EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39(16):2264\u20132272","journal-title":"Eur J Cancer"},{"issue":"3","key":"6967_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1345\/aph.1G516","volume":"40","author":"D Weycker","year":"2006","unstructured":"Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40(3):402\u2013407","journal-title":"Ann Pharmacother"},{"issue":"2 Suppl","key":"6967_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.18553\/jmcp.2003.9.s2.15","volume":"9","author":"SD Scott","year":"2003","unstructured":"Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Stolshek BS (2003) Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin\u2019s lymphoma treated with chemotherapy. J Manag Care Pharm 9(2 Suppl):15\u201321","journal-title":"J Manag Care Pharm"},{"issue":"7","key":"6967_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/MLR.0b013e318215c42e","volume":"49","author":"SS Rajan","year":"2011","unstructured":"Rajan SS, Lyman GH, Stearns SC, Carpenter WR (2011) Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. Med Care 49(7):649\u2013657","journal-title":"Med Care"},{"issue":"5","key":"6967_CR23","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/1078155215625459","volume":"22","author":"S Mitchell","year":"2016","unstructured":"Mitchell S, Li X, Woods M et al (2016) Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review. J Oncol Pharm Pract 22(5):702\u2013716","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"6967_CR24","first-page":"976","volume":"24","author":"LS Schwartzberg","year":"2018","unstructured":"Schwartzberg LS, Lal LS, Balu S et al (2018) Clinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer undergoing chemotherapy. J Manag Care Spec Pharm 24(10):976\u2013984","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"6967_CR25","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00520-015-3036-7","volume":"24","author":"D Weycker","year":"2016","unstructured":"Weycker D, Li X, Figueredo J, Barron R, Tzivelekis S, Hagiwara M (2016) Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Supportive care in cancer\u202f: official journal of the Multinational Association of Supportive Care in Cancer 24(5):2309\u20132316","journal-title":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"3","key":"6967_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JOP.091094","volume":"6","author":"HA Burris","year":"2010","unstructured":"Burris HA, Belani CP, Kaufman PA et al (2010) Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and Non-Hodgkin\u2019s Lymphoma: Results of four multicenter, double-blind, randomized phase ii studies. J Oncol Pract 6(3):133\u2013140","journal-title":"J Oncol Pract"},{"key":"6967_CR27","unstructured":"Food and Drug Administration. Pegfilgrastim [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125031s180lbl.pdf. Accessed 3 Dec\u00a02019"},{"issue":"12","key":"6967_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/jnci\/djr152","volume":"103","author":"AL Potosky","year":"2011","unstructured":"Potosky AL, Malin JL, Kim B et al (2011) Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst 103(12):979\u2013982","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"6967_CR29","first-page":"678","volume":"16","author":"SD Ramsey","year":"2010","unstructured":"Ramsey SD, McCune JS, Blough DK et al (2010) Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care 16(9):678\u2013686","journal-title":"Am J Manag Care"},{"issue":"2","key":"6967_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00520-017-3863-9","volume":"26","author":"RK Goyal","year":"2018","unstructured":"Goyal RK, Tzivelekis S, Rothman KJ, Candrilli SD, Kaye JA (2018) Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer. Supportive care in cancer\u202f: official journal of the Multinational Association of Supportive Care in Cancer 26(2):539\u2013548","journal-title":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"8","key":"6967_CR31","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00520-014-2184-5","volume":"22","author":"WJ Langeberg","year":"2014","unstructured":"Langeberg WJ, Siozon CC, Page JH, Morrow PK, Chia VM (2014) Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin\u2019s lymphoma. Supportive care in cancer\u202f: official journal of the Multinational Association of Supportive Care in Cancer 22(8):2167\u20132175","journal-title":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"6","key":"6967_CR32","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/cam4.344","volume":"3","author":"G Barnes","year":"2014","unstructured":"Barnes G, Pathak A, Schwartzberg L (2014) G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med 3(6):1477\u20131484","journal-title":"Cancer Med"},{"issue":"8","key":"6967_CR33","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jgo.2020.06.018","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, Liu J, Gong T et al (2020) Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriar Oncol 11(8):1309\u20131315","journal-title":"J Geriar Oncol"},{"key":"6967_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/CLEP.S105613","volume":"9","author":"KE Mues","year":"2017","unstructured":"Mues KE, Liede A, Liu J et al (2017) Use of the Medicare database in epidemiologic and health services research: a valuable source of realworld evidence on the older and disabled populations in the US. Clin Epidemiol 9:267\u2013277","journal-title":"Clin Epidemiol"},{"issue":"2","key":"6967_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00520-016-3421-x","volume":"25","author":"D Weycker","year":"2017","unstructured":"Weycker D, Li X, Tzivelekis S et al (2017) Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with Colony-stimulating factor. Support Care Cancer 25(2):439\u2013447","journal-title":"Support Care Cancer"},{"issue":"11","key":"6967_CR36","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130\u20131139","journal-title":"Med Care"},{"key":"6967_CR37","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676\u2013682","journal-title":"Am J Epidemiol"},{"key":"6967_CR38","unstructured":"Food and Drug Administration. Pegfilgrastim-jmdb [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761075s000lbl.pdf. Accessed 9 Feb\u00a02021"},{"key":"6967_CR39","unstructured":"Food and Drug Administration. Pegfilgrastim-cbqv [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761039s000lbl.pdf. Accessed 9 Feb\u00a02021"},{"key":"6967_CR40","unstructured":"Food and Drug Administration. Filgrastim [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/103353s5183lbl.pdf. Accessed 9 Feb\u00a02021"},{"key":"6967_CR41","unstructured":"Food and Drug Administration. Tbo-filgrastim [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125294s0000lbl.pdf. Accessed 9 Feb\u00a02021"},{"key":"6967_CR42","unstructured":"Food and Drug Admnistration. Filgrastim-sndz [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125553lbl.pdf. Accessed 9 Feb\u00a02021"},{"key":"6967_CR43","unstructured":"Food and Drug Administration. Filgrastim-aafi [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761080s000lbl.pdf. Accessed 9 Feb\u00a02021"},{"issue":"1","key":"6967_CR44","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1186\/s12885-018-4986-1","volume":"18","author":"H Roch\u00e9","year":"2018","unstructured":"Roch\u00e9 H, Eymard JC, Radji A et al (2018) Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOH\u00e9 study). BMC Cancer 18(1):1127","journal-title":"BMC Cancer"},{"issue":"11","key":"6967_CR45","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1007\/s12325-018-0798-6","volume":"35","author":"P Cornes","year":"2018","unstructured":"Cornes P, Gascon P, Chan S et al (2018) Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia. Adv Ther 35(11):1816\u20131829","journal-title":"Adv Ther"},{"issue":"10","key":"6967_CR46","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s00520-017-3720-x","volume":"25","author":"R Sosa","year":"2017","unstructured":"Sosa R, Li S, Molony JT, Liu J, Stryker S, Collins AJ (2017) Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database. Support Care Cancer 25(10):3123\u20133132","journal-title":"Support Care Cancer"},{"key":"6967_CR47","doi-asserted-by":"crossref","unstructured":"Lepr\u00eatre S, Maloisel F, Kamioner D, Berthou C, Albrand H (2015) Safety of biosimilar filgrastim in patients with breast cancer undergoing neutropenia-inducing chemotherapy: A subanalysis of the NEXT study. J Clin Oncol 33(15_suppl):e20711\u2013e20711","DOI":"10.1200\/jco.2015.33.15_suppl.e20711"},{"issue":"2","key":"6967_CR48","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00520-015-2861-z","volume":"24","author":"P Gasc\u00f3n","year":"2016","unstructured":"Gasc\u00f3n P, Aapro M, Ludwig H et al (2016) Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer 24(2):911\u2013925","journal-title":"Support Care Cancer"},{"issue":"4","key":"6967_CR49","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000381318","volume":"38","author":"H Tesch","year":"2015","unstructured":"Tesch H, Ulsh\u00f6fer T, Vehling-Kaiser U, Ottillinger B, Bulenda D, Turner M (2015) Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns. Oncol Res Treat 38(4):146\u2013152","journal-title":"Oncol Res Treat"},{"issue":"3","key":"6967_CR50","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2354.2008.00959.x","volume":"18","author":"D Almenar","year":"2009","unstructured":"Almenar D, Mayans J, Juan O et al (2009) Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain\u2013results of the LEARN Study. Eur J Cancer Care 18(3):280\u2013286","journal-title":"Eur J Cancer Care"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06967-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06967-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06967-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T09:34:39Z","timestamp":1653557679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06967-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6967"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06967-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"21 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Office for Human Subjects Research of Hennepin Healthcare System.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JS, MK, and BB are employees of and hold stock in Amgen, INC; TG, YP, and SL are employees of Chronic Disease Research Group; DH, no conflicts; PG is currently an employee of and holds stock in Vertex Pharmaceuticals and is a former employee of Amgen and currently holds stock in Amgen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}